Hyperbaric oxygen therapy (HBOT) involves breathing pure oxygen inside a pressurised chamber. The pressure forces oxygen into the blood plasma and deep into tissues at concentrations far exceeding what normal breathing delivers. In the context of Lyme disease, this creates an environment that is directly hostile to the bacteria responsible for the infection.
This page explains the mechanism, summarises what research exists, describes what a course of treatment actually involves, and is honest about the risks and limitations.
Why oxygen is a problem for Borrelia
Borrelia burgdorferi is a microaerophile — an organism that tolerates only very low levels of oxygen and cannot function properly in oxygen-rich environments. In normal body tissues, oxygen concentrations are sufficient to allow Borrelia to survive. Under hyperbaric conditions, they are not.
Under hyperbaric pressure, blood plasma becomes saturated with dissolved oxygen. This oxygen penetrates deep into tissues — including connective tissue, joint capsules, and areas of the brain — where normal circulation is poor and where Borrelia tends to persist. In these oxygen-flooded environments, the bacteria are weakened and die.
Borrelia forms protective biofilms that physically shield the bacteria from antibiotics. The fibroblasts (connective tissue cells) that the bacteria colonise also provide shelter from conventional treatment. Pressurised oxygen reaches these sheltered locations differently from drugs — it dissolves directly into plasma and diffuses through tissue rather than requiring active transport. This is why HBOT is discussed as an adjunct to antibiotics rather than a replacement: it reaches where antibiotics cannot.
Beyond the direct effect on bacteria, HBOT stimulates stem cell release from bone marrow, reduces neurological inflammation, improves microcirculation, and promotes tissue repair. In patients with neurological Lyme symptoms, these secondary effects may contribute substantially to symptom improvement.
The clinical evidence
The evidence base for HBOT in Lyme disease is small but not negligible — it is the most clinically documented of the non-antibiotic approaches in this category.
The foundational study. W.P. Fife, Ph.D. and R.A. Neubauer, MD treated 91 patients with chronic Lyme disease using HBOT at 2.4 atmospheres, twice daily, five days a week. At the end of treatment, 84.8% of patients showed significant clinical improvement, confirmed by changes in SPECT brain scans (single photon emission computerised tomography, which images brain blood flow and activity).
The study also noted that fibroblasts protecting Borrelia from antibiotics were not able to protect the bacteria from pressurised oxygen — providing a biological rationale for why HBOT reaches bacteria that antibiotics cannot.
A 31-year-old man with chronic Lyme disease had undergone years of antibiotic treatment without resolution of symptoms. After thirty 90-minute HBOT sessions, his joint pain disappeared, his eye twitch resolved, his sleep disorder improved, and his short-term memory returned. Published in the Journal of the Chinese Medical Association.
The Fife study, though often cited, was not a randomised controlled trial — it had no placebo group and was conducted at a single centre. The Taiwan case is a single patient. HBOT is not FDA-approved for Lyme disease, and no large-scale RCT has been conducted. The Global Lyme Alliance notes that clinical evidence is "limited but present." This does not mean HBOT does not work — it means it has not been studied at the scale required to make definitive claims.
What a course of HBOT looks like
There is no single universally accepted protocol for Lyme disease. The following reflects the parameters used in the Fife study and those reported by specialised Lyme clinics — individual treatment centres may vary.
A note on "soft" chambers: portable inflatable chambers used at home operate at pressures of approximately 1.3 ATA — far below the 2.0–2.4 ATA range relevant for Lyme disease. The evidence does not support soft chambers as an equivalent to clinical HBOT. This is an important distinction when evaluating cost and accessibility.
What can go wrong
HBOT is generally well-tolerated when administered correctly in a medical setting, but it is not without risk. The following should be discussed with both a hyperbaric physician and your treating Lyme doctor before starting.
- Barotrauma — pressure changes can cause ear pain, eardrum rupture, or sinus injury. Most commonly mild and manageable. Ear equalisation technique is taught before treatment begins.
- Oxygen toxicity seizures — rare but possible at higher pressures or with prolonged sessions. Medical-grade facilities monitor for this throughout treatment.
- Temporary visual changes — transient myopia (nearsightedness) can develop during a long course of HBOT; reverses after treatment ends in most cases.
- Lung complications — pneumothorax (lung collapse) is a rare but serious risk; anyone with a history of lung disease should be evaluated carefully.
- Hypoglycaemia — patients with insulin-dependent diabetes require careful monitoring, as HBOT can lower blood sugar.
- Herxheimer reaction — as with any effective Lyme treatment, symptom flares ("Herx") can occur as bacteria die off, particularly in the early sessions. This is not a contraindication but should be anticipated.
- Pacemakers and implants — certain metallic implants and electronic devices are contraindicated in pressurised chambers. A full pre-treatment screening is standard at reputable centres.
Cost, access, and realistic expectations
A full course of 40 sessions at a private hyperbaric centre typically costs between €3,000 and €8,000 depending on location, centre, and session length. HBOT for Lyme disease is not reimbursed by public health insurance in most countries, as it is not an officially approved indication. This is one of the most significant barriers to access.
HBOT is not a cure in the sense of complete bacterial eradication with a single course. The Fife study showed improvement in 84.8% of patients — not elimination of all symptoms in all patients. Many practitioners use it as one layer of a multi-pronged approach: reducing bacterial load, improving neurological symptoms, and giving the immune system room to work, while antibiotic or herbal protocols continue in parallel.
Look for centres with medical supervision and clinical-grade chambers capable of reaching at least 2.0 ATA. Ask specifically about their experience with Lyme disease patients and their protocols. Centres operating "wellness" soft chambers at 1.3 ATA are offering a different — and in this context, therapeutically insufficient — product.
Other approaches in this section
Ozone therapy works on a related principle — creating a hostile oxidative environment for Borrelia. The evidence is at an earlier stage than HBOT, but the biological rationale overlaps significantly.
Healing mentality checkpoint
HBOT is expensive, time-intensive, and not available everywhere. If you cannot access it — or cannot afford it — that is not a failure of your treatment strategy. The most effective Lyme treatment plan is the one you can actually sustain. There are other paths.
Read about healing mentality →Sources & further reading
- Fife W.P., Neubauer R.A. — Hyperbaric oxygenation for Lyme vasculitis, Texas A&M University (1998)
- Huang C.Y. et al. — Hyperbaric oxygen therapy as an effective adjunctive treatment for chronic Lyme disease, Journal of the Chinese Medical Association (2014)
- Lantos P.M. et al. — Hyperbaric Oxygen Therapy and Chronic Lyme Disease: The Controversy and the Evidence, Springer (2016)
- Global Lyme Alliance — HBOT and Lyme disease: overview and evidence assessment (globallymealliance.org)
- Project Lyme — interview with Dr. Alexander Alvarez, certified hyperbaric physician, Aviv Clinics
- Mayo Clinic — Hyperbaric oxygen therapy: risks and indications (mayoclinic.org)
Last updated: March 2026